LarsMWagnerMD

Clinical Trials

• N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma Start of enrollment: 2004 May 01

  Completed

  Phase 1

• Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors Start of enrollment: 2005 Oct 01

  Completed

  Phase 1

• Combination Chemotherapy and Radiation Therapy in Treating Younger Patients Who Are Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Gliomas Start of enrollment: 2005 Aug 01

  Completed

  Not Applicable

• Neuropsychological and Behavioral Testing in Younger Patients With Cancer Start of enrollment: 2009 Feb 27

  Recruiting

• A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors Start of enrollment: 2008 Oct 01

  Completed

  Phase 1

• Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 14

  Active, not recruiting

  Phase 3

• Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Aug 09

  Completed

• Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22

  Completed

  Phase 2

• Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Jun 20

  Active, not recruiting

  Phase 3

• Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients Start of enrollment: 2012 Jun 01
• Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Start of enrollment: 2013 Feb 12

  Completed

  Phase 2

• Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2013 Jan 31

  Completed

  Phase 1, Phase 2

• Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas Start of enrollment: 2013 Jun 17

  Active, not recruiting

• Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma Start of enrollment: 2013 Nov 13

  Completed

  Phase 2

• Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma Start of enrollment: 2014 Aug 01

  Completed

  Phase 2

• Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma Start of enrollment: 2014 Oct 04

  Active, not recruiting

  Phase 3

• Use of Propranolol to Reduce FDG Uptake in Brown Adipose Tissue in Pediatric Cancer Patients PET Scans Start of enrollment: 2014 Jul 01

  Completed

• Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Start of enrollment: 2014 Jul 11

  Active, not recruiting

  Phase 2, Phase 3

• Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 01
• Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma Start of enrollment: 2016 Oct 25

  Active, not recruiting

  Phase 2

• Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma Start of enrollment: 2019 Jul 08

  Active, not recruiting

  Phase 2

• Evolutionary Therapy for Rhabdomyosarcoma Start of enrollment: 2020 Sep 27

  Recruiting

  Phase 2

  Roles: Contact, Principal Investigator

• Join now to see all